HCWB · NASDAQ
HCW Biologics (HCWB) Stock Price & Fundamentals
HCW Biologics (HCWB) closed at $607.25 on Oct 9, 2026, up 0.08% from the previous close of $606.75.
Share price, past year
1Y +21.03%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $607.25 |
| Sep 30, 2026 | $593.98 |
| Aug 31, 2026 | $616.94 |
| Jul 31, 2026 | $584.20 |
| Jun 30, 2026 | $593.57 |
| May 29, 2026 | $618.83 |
| Apr 30, 2026 | $638.87 |
| Mar 31, 2026 | $627.17 |
| Feb 27, 2026 | $630.49 |
| Jan 30, 2026 | $617.05 |
| Dec 31, 2025 | $546.67 |
| Nov 28, 2025 | $508.19 |
| Oct 31, 2025 | $514.18 |
Key statistics
- Market cap
- $1.12B
- P/E (TTM)
- 19.2
- EPS (TTM)
- $31.70
- Revenue (TTM)
- $6.66M
- Net income (TTM)
- −$5.58M
- Shares outstanding
- 1.8M
- Dividend yield
- —
- 52-week range
- $501.72 – $672.46
HCW Biologics's market cap is $1.12B, based on a share price of $607.25 and 1.8M shares outstanding as of Aug 12, 2026.
Financials
HCW Biologics reported revenue of $54.23K for fiscal 2025, down 97.89% from fiscal 2024.
HCW Biologics reported a net loss of $7.96M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $54.23K | −97.9% | −$7.96M | −14,677.1% | −$10.63 | −$13.39M |
| FY2024ended Dec 31, 2024 | $2.57M | −9.7% | −$30.02M | −1,169.7% | −$30.96 | −$14.49M |
| FY2023ended Dec 31, 2023 | $2.84M | −57.7% | −$24.99M | −879.5% | −$0.70 | −$28.72M |
| FY2022ended Dec 31, 2022 | $6.72M | — | −$14.90M | −221.7% | −$0.42 | −$20.66M |
| FY2021ended Dec 31, 2021 | $0.00 | −100.0% | −$12.86M | — | −$0.69 | −$11.02M |
| FY2020ended Dec 31, 2020 | $4.10M | — | −$5.80M | −141.5% | −$1.49 | −$10.62M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $121.73K | −$5.22M | −$11.58 |
| Q1 FY2026ended Mar 31, 2026 | $6.50M | $3.47M | $1.39 |
| Q4 FY2025ended Dec 31, 2025 | $27.01K | $719.23K | $43.91 |
| Q3 FY2025ended Sep 30, 2025 | $15.61K | −$4.55M | −$2.02 |
| Q2 FY2025ended Jun 30, 2025 | $6.55K | −$1.93M | −$40.72 |
| Q1 FY2025ended Mar 31, 2025 | $5.07K | −$2.20M | −$11.80 |
| Q4 FY2024ended Dec 31, 2024 | $394.80K | −$3.37M | −$10.47 |
| Q3 FY2024ended Sep 30, 2024 | $426.42K | −$3.90M | −$4.13 |
Company profile
- Name
- HCW Biologics Inc.
- Ticker
- HCWB
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 2929 N Commerce Pkwy, Miramar, FL 33025
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001828673
Recent SEC filings
- Sep 24, 2026
- Sep 10, 2026
- Sep 8, 2026
- Aug 14, 2026
- Aug 14, 2026
- Aug 14, 2026
- Aug 14, 2026
- Jul 29, 2026
Frequently asked questions
What is HCW Biologics's stock price?
HCW Biologics (HCWB) closed at $607.25 on Oct 9, 2026, up 0.08% from the previous close of $606.75.
What is HCW Biologics's market cap?
HCW Biologics's market cap is $1.12B, based on a share price of $607.25 and 1.8M shares outstanding as of Aug 12, 2026.
How much revenue does HCW Biologics make?
HCW Biologics reported revenue of $54.23K for fiscal 2025, down 97.89% from fiscal 2024.
What is HCWB's P/E ratio?
HCW Biologics's price-to-earnings ratio is 19.2, based on trailing twelve-month diluted EPS of $31.70.
Does HCW Biologics pay a dividend?
HCW Biologics's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from HCW Biologics Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures